Benzinga

Benzinga

Benzinga

venerdì, agosto 21

West Pharmaceutical Services Inc

WSTNYSE
Trade with Public
Trade with Public
$353.08
-0.69-0.2%
In chiusura: Aug 21, 5:00 PM EST
$353.08
N/A
Post-mercato: 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

West Pharmaceutical Servs Financials

West Pharmaceutical Servs (WST) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum

West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.
Vandana Singh

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights

PRO
West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est

West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345 billion-$3.380
Benzinga Newsdesk

PRO
West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est

West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..
Benzinga Newsdesk

PRO
West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est

West Pharmaceutical Servs (NYSE:WST) is looking for Q3 Adj EPS of $2.14-$2.24 vs $2.12 analyst estimate. sees sales of $820.000 million-$835.000 million vs $815.707 million analyst estimate.
Benzinga Newsdesk

PRO
West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate

West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.08 by 13.94 percent. This is a 28.8 percent increase over earnings of $1.84 per share
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved